

# Medication Adherence In Egypt: A Systematic Review

Ahmed.M.Kamel, B.Pharm<sup>1</sup>, Khatiwada AP, M.Pharm<sup>1</sup>, Qian J, Ph.D,<sup>1</sup>

<sup>1</sup>Department of Health Outcomes Research and Policy, Harrison College of Pharmacy, Auburn University



# BACKGROUND


Poor medication adherence is considered a significant healthcare issue leading to suboptimal health outcomes and increased healthcare costs, especially in developing countries. This systematic review systemized existing evidence in assessing medication adherence in the Egyptian population.

# **OBJECTIVE**

To have an overview of medication adherence research among people in Egypt.

# **METHODS**

Original research articles reporting quantitative results in medication adherence among the Egyptian population were systematically searched from six databases including PubMed, Scopus, Web of Science, Virtual Health Library, New York Academy of Medicine, and System for information on Grey Literature in Europe from inception till November 22, 2022. Two authors screened the title and abstract independently followed by a full-text review, and studies were included upon consensus. We included original papers reporting quantitative results in medication adherence among the Egyptian population. No restrictions regarding study design, language, publication date, medication therapeutical class, disease, or medication adherence measures were placed.




PRISMA 2020 flow diagram of the screening process

|                                  | Ch  | aracteristics of included studies   |                                 |          |         |              |
|----------------------------------|---|---|---------------------------------|----------|---------|--------------|
|                                  | Population  | Adherence Measurement   | <b>Medication Adherence (N)</b> |          |         | Quality      |
| ID                               |   |   | Low                             | Medium   | High    | Assess ment* |
| Abdul-Sattar<br>2014(1)          | systemic lupus erythematosus  | The Compliance Questionnaire for Rheumatology-19                                | 38                              | 42       |         | Fair         |
| lgameel 2020(2)                  | residents in the elderly homes  | Structured interview  | 8                               | 39       | 16      | Poor         |
| li 2016(3)                       | vitiligo patients   | (MMAS-8)  | 148                             | 76       | ·       | Poor         |
| wwad 2021(4)                     |   | Self-reported missed medication doses   | 1312                            | 1469     |         | Fair         |
| . ,                              | Glaucoma Patients   |   | 1224                            | 348      |         |              |
| Ebid 2020(5)                     | Type-2 Diabetic Patients  | (MMAS-8)  | 15.1± 2.1                       | #        |         | Poor         |
|                                  |   |   | 12.7± 2.3                       |          |         |              |
| smael 2019(6)                    | Epileptic Patients  | self-reported, medication-taking behavior scale used by Pande Ayu et al.        | 5.27 ± 0.95#<br>6.3 ± 1.12#     |          |         | Fair         |
| adallah 2015(7)                  | Rheumatoid Arthritis Patients'  | Arabic version of (MMAS-8)  | 13                              | 127      | 0       | Fair         |
| ammad 2022(8)                    | Inflammatory rheumatic Diseases   | Arabic version of (MMAS-8)  | 10                              | 43       | 3       | Fair         |
| bdel Khalek<br>015(9)            | Acute lymphoblastic Leukemia, oral 6-mercaptopurine adherence   | serum 6-MP level and a questionnaire  | 72                              | 57       |         | Poor         |
| amal 2021(10)                    | patients with recurrent ischemic stroke   | Hospital records  | 100                             | 22       |         | Poor         |
| /Jahran 2020(11)                 | rheumatoid arthritis patients, disease-<br>modifying anti-rheumatic drugs<br>adherence                                | Clinician Rating Scale (CRS)  | 19                              | 23       | 31      | Poor         |
| l Malla 2013(12)                 | Children with cancer  | Reported by children's parents  | 123                             | 58       |         | Poor         |
| ayed 2019(13)                    | Behçet's disease patients   | Compliance Questionnaire of Rheumatology (CQR)                                  | 69.2 ± 11.                      |          |         | Poor         |
| eeneldin                         | breast cancer patients, Oral hormonal   | Self-reported numbers of days receiving the medications                         |                                 | 131      |         | Fair         |
| 012(14)                          | therapy during Ramadan fasting  | divided by the total days   | 6                               | 133      |         | l GIII       |
|                                  | Lupus Nephritis Flares,   | divided by the total days   | 49                              | 17       |         | Fair         |
| li 2020(15)                      | Immunosuppressive Medications adherence   | The Morisky, Green, and Levine (MGL) Adherence Scale                            | 19                              | 19       |         | lan          |
| henawy<br>022(16)                | Children with Type 1 Diabetes, Insulin Treatment adherence  | Arabic version of the four-item MGL   | 105                             | 161      | 134     | Poor         |
| abib 2018(17)                    | Diabetic Macular Edema patients, Intravitreal Anti-Vascular Endothelial   | Adherence Scale  Hospital records of dropped/delayed visits or injection        | 71                              | 272      |         | Fair         |
| eissam 2015(18)                  | Growth Factor drugs adherence. type 2 diabetics, oral anti-diabetic   | Delgado and Lima treatment adherence scale                                      | 99                              | 179      | 98      | Poor         |
|                                  | adnerence   |   |                                 |          |         |              |
| rahim 2010(19)                   | diabetic patients   | Self-reported   | 19                              | 236      | 345     | Poor         |
| alama 2020(20)                   | Type 2 diabetic patients  | Arabic version of the (MMAS-8)  | 45                              | 24       | 13      | Fair         |
| audi 2020(21)                    | Type 2 diabetic patients  | Arabic version of the (MMAS-8)  | 101                             | 78       | 86      | Fair         |
| hams 2010(22)                    | Type 2 diabetic patients  | Delgado and Lima treatment adherence scale                                      | 37                              | 101      | 88      | Fair         |
| assanein<br>020(23)              | Essential hypertensive patients, Antihypertensive fixed dose combination adherence                                    | (MMAS-8) scale  | 652                             | 523      | 825     | Fair         |
| lussein 2020(24)                 | Hypertensive patients   | Structured interview  | 1304                            | 1116     |         | Fair         |
| ldeib 2018(25)                   | metastatic colorectal or gastric cancer<br>treated patients, Telephone-Based<br>Follow-Up effect on adherence to Oral | pill count method   | 1                               | 36<br>43 |         | Poor         |
| baza 2017(26)                    | Capecitabine-Based Chemotherapy  Diabetic patients, SMS messages effect on diabetes self-management                   | (MMAS-4)  | 3.94 ± 1.20#<br>3.90 ± 1.21#    |          | Poor    |              |
| 1ohsen 2019(27)                  | Chronic obstructive pulmonary disease   | (MMAS-8)  | 60                              | 73       |         | Fair         |
| li 2020(28)                      | patients Asthma nationts  | (MMAS-8)  | 39                              | 25       | 46      | Fair         |
|                                  | Asthma patients   |   | 624                             | 415      | 40      | Fair         |
| assam 2020(29)<br>adner 2020(30) | Asthma patients  chronic obstructive pulmonary disease patients   | (MMAS-4) Patients who had decided to stop treatment was considered non-adherent | 170<br>631                      | 415      |         | High         |
| -Missiry<br>015(31)              | Impact of medication adherence on schizophrenic patients  | the Brief Adherence Rating Scale (BARS)   | 75                              | 34       |         | Poor         |
| kasha 2020(32)                   | Bipolar I disorder patients   | (MMAS-8)  | 64                              | 25       | 21      | Fair         |
| halil 2021(33)                   | bipolar I disorder patients   | (MMAS-8)  | 64                              | 25       | 21      | Poor         |
|                                  | •   |   |                                 |          |         | Poor         |
| Sultan 2015(34)                  | Schizophrenic patients  | Brief Adherence Rating Scale  | 75                              | 34       | 5.40.44 |              |

MMAS; Morisky Medication Adherence Scale. #; Adherence is measured in Mean ± SD. \*Quality assessment was done using NIH tool a score was given for each item, A score of 13–14 was good, 9–12 fair and studies scoring below 9 were deemed to be of poor quality (35).

# RESULT



The frequency of papers for each Disease category

# SUMMARY OF FINDINGS

### Study characteristics

- There were 26 cross-sectional studies (1-25), five prospective longitudinal studies (26-31), and three randomized controlled trials (32-34).
- Fifteen studies measured medication adherence using either four or eight items MMAS (2, 3, 7, 8, 14, 18, 19, 22-25, 29, 30, 32, 34), two studies used Delgado and Lima scale (16, 20), two studies used structured interview (21, 26), two studies used the Brief Adherence Rating Scale (28, 31), four studies used self-reported missed medication doses (4, 13, 17, 27), one study used Pande Ayu scale (6), one study used serum 6-MP level (10). Two studies used hospital records (9, 15), one study used clinical rating scale (11), one study used parents to report children adherence (5), two studies used Compliance Questionnaire of Rheumatology (1, 12), and one study used pill count method (33).
- Out of 34 included studies, 16 showed poor quality, 17 showed fair quality, and only one study demonstrated high quality using the NIH quality assessment tool.

## Medication adherence

- Seven studies focused on diabetic patients' medication adherence, with 5 reporting an adherence rate of less than 50% and 2 reporting a rate of more than 50% (14-20).
- Two studies reported chronic obstructive pulmonary disease with a rate of more than 50% (25, 27).
- Asthmatic patients were reported by two studies with more than half of the patients being non-adherent (23, 24).
- Four studies included psychiatric patients (two bi-bolar and two schizophrenia) with a medication adherence rate lower than half (28-31).
- Hypertensive patients were involved in two studies showing less than 50% medication adherence rate (21, 22).
- Three Trials showed interventions to improve medication adherence.
- massages, telephone-based follow-up, and clinical pharmacists (32-34).
- Only clinical pharmacist intervention group showed significant increase in medication adherence (32).

# CONCLUSIONS

- Our study found a low medication adherence rate among Egyptians, with few studies on medication adherence improvement interventions.
- Further research is needed to develop and implement effective interventions to improve medication adherence in Egypt.